An interventional study of Probiotics and heat-treated of Lactobacillus paracasei HT-PS23 in Elderly, Muscle Loss and Depression, sponsored by Chi-Chang Huang. Completed at 1 site in Taiwan. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by Chi-Chang Huang · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Muscular Atrophy with a site in Taiwan — 1 open to participants now, 3 under way, 1 of them phase 3. Muscular Atrophy · Taiwan.
Among the 23 studies in Muscular Atrophy with a site in Taiwan, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 13 with no phase, and was the 20th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →1 of the 23 studies in Muscular Atrophy with a site in Taiwan is open now. Recruiting first, the newest first:
Shin Kong Wu Ho-Su Memorial Hospital · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2023.
This study's enrollment of 119 is above the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 100 across the 22 interventional studies, 600 across the 1 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Chi-Chang Huang is the lead sponsor of 5 studies on the registry; none are open to participants now.
Chi-Chang Huang has 1 study filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Muscular Atrophy with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study refers to the supplementation of PS23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people.
Taiwan has become an aging society in recent years. There are important issues to attenuate aging and activate the potential capacity of elderly population. The physical function of middle-aged and older people will degenerate with age and produce age-related diseases. Common symptoms are organ function deterioration, and old age disability caused by malnutrition and muscle loss is also a common care problem. Therefore, how to prevent the complications of muscle loss is one of the important ten years of geriatric research. Although past research has been confirmed, it can improve the debilitating condition of the elderly through nutrition counseling and exercise intervention. However, there is not much in-depth discussion on how probiotics can improve muscle loss and delay symptoms in elderly people. Therefore, this study refers to the supplementation of PS23 in human experiments to help the elderly maintain muscle mass, delay muscle loss, promote physical activity, and delay the occurrence of disability and debilitation in elderly people. One hundred and twenty elderly people will be recruited and then divided into three groups with 40 people in each group: (A) placebo group, (B) PS23 probiotic group, (C) PS23-HT prebiotic group, supplemented for 12 weeks. The diet record, functional test and muscle mass will be carried out every six weeks after the start, to understand whether PS23 is effective in improving muscle loss and weakness in elderly people.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Probiotic capsules contain 10 billion CFU (colony forming units) of Lactobacillus paracasei, 2 caps daily use
Dietary Supplement: Probiotics
heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
Dietary Supplement: heat-treated of Lactobacillus paracasei HT-PS23
The placebo capsule contains microcrystalline cellulose, 2 caps daily use
Dietary Supplement: Placebo
Lactobacillus paracasei PS23 will be used in this study
heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
The placebo capsule contains microcrystalline cellulose, 2 caps daily use
muscle mass
Use dual-energy X-ray absorptiometry, DXA (Lunar iDXA, GE Healthcare, IL, USA) for no-entry measurement to determine muscle mass
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
30 seconds chair stand test
30 seconds chair stand test will be used as a self-test. Number of stands will be counted.
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Grip strength
Use the armed grip machine to measure, hold each of the left and right hands three times until they are weak, and record the maximum value
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Generalized Anxiety Disorder 7-Item, GAD-7
The GAD-7 Anxiety Questionnaire involves 7 items assessing how often participants have felt bothered by anxiety-related problems over the past two weeks. Each item is rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0-21; where 0-4 = minimal anxiety; 5-9 = mild anxiety; 10-14 = moderate anxiety; 15-21 = severe anxiety
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Geriatric Depression Scale, GDS
It consists of 30 questions questioning the mood in the last week. This short form consists of 15 questions questioning the mood of the patient. The answers are given according to the feelings in the last week; The answers are "yes" or "no" and 1 point is given for "yes" or "no" answers depending on the question. For the long form: Normal 0 - 10, Mild 11 - 20, Moderate to Severe 21 - 30.For the short form: Normal 0 - 4, Mild 5 - 9, Moderate to Severe 10 - 15.
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Q-LES-Q
Participants who receive app-CBT will have greater improvement on quality of life, assessed using The Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (Q-LES-Q). The Q-LES-Q-SF is a self-report measure of subjective quality of life, containing Likert items ranging from 1 (Very Poor) to 5 (Very Good). Total scores are presented as a percentage of the maximum value (i.e., ranging from 0 to 100, with higher scores indicating greater quality of life).
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Visual Analogue Scale for GI symptoms, VAS-GI
Visual Analogue Scale for GI symptoms, VAS-GI (visual analogue scale, VAS 0-10) was designed to measure the response of symptoms and well-being in patients after taking probiotics
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
PGI-C
The PGIC is a scale participants use to rate the level of change they have experienced following treatment. The PGIC is a 7-point scale from 1 (very much better) to 7 (very much worse).
Time frame: From Baseline to 12 Weeks Assessed
10 meter walk
Use a pyramid and a measuring tape to measure a distance of ten meters, and ask the subject to stand up from the chair, go around the pyramid and sit down, and record the time
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
fat percentage
Use dual-energy X-ray absorptiometry, DXA (Lunar iDXA, GE Healthcare, IL, USA) for no-entry measurement to determine fat percentage
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
One-leg stance test
To evaluate static balance ability
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Get Up and Go test
To evaluate functional walking ability
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Sit and Reach Test
To evaluate lower-limb strength and flexibility
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Cardiorespiratory fitness
2-min step test to assess the functional capacity of the respiratory and cardiovascular systems
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Safety assessment - AST
Safety is assessed function of liver and kidney such as AST (8-38 IU/L).
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Safety assessment - ALT
Safety is assessed function of liver and kidney such as ALT (4-44 IU/L)
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Safety assessment - Bun
Safety is assessed function of liver and kidney such as Bun (6-20 mg/dl)
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Safety assessment - Creatinine
Safety is assessed function of liver and kidney such as Creatinine (0.6-1.3 mg/dl)
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Stress assessment - difference of Testosterone level
To assess inflammation indicators, used commercial kit human Testosterone (Cayman, Mich, USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis Male 265-923 (in ng/dl) Female 15-70 (in ng/dl) for 19 years and older
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Difference in Oxidative stress - blood level of HSCRP
To assess inflammation indicators, used commercial kit human CRP (Cayman, Mich, USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Gut microbiota
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota in Stool samples before and after probiotics
Time frame: From Baseline 12 Weeks Assessed
Level of Growth Differentiation Factor-15
Level of Growth Differentiation Factor-15
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Change in Insulin Sensitivity
Change in fasting glucose
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
The serum IL-6 level
the measurement of serum IL-6 level in blood
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
TNF-a determination using ELISA
A serum level of TNF-a was determined by quantitative sandwich enzyme immunoassay (R\&D Systems, Inc., Minneapolis, MN, USA) guided by to the manufacturer's instructions. The intensity of the color was measured at 490 nm.
Time frame: From Baseline, 6 weeks and 12 Weeks Assessed
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Nov 2023, 3 months.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 3 months is below that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chi-Chang Huang